Home › Trial NCT01738594
Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
- Trial IDNCT01738594
- StatusTerminated
- PhasePhase 1
- Study typeInterventional
- SponsorNorthwestern University
- Enrollment7
- Start date2013-03-22
- ConditionsRecurrent Cutaneous T-cell Non-Hodgkin Lymphoma · Recurrent Mycosis Fungoides/Sezary Syndrome · Stage I Cutaneous T-cell Non-Hodgkin Lymphoma · Stage IA Mycosis Fungoides/Sezary Syndrome · Stage IB Mycosis Fungoides/Sezary Syndrome · Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.